GOAL: To determine the risk of future biopsy-verified IgA nephropathy (IgAN) among individuals with biopsy-verified celiac disease (CD). BACKGROUND: Individuals with CD suffer increased risk of end-stage renal disease. An association between CD and IgAN has been suggested; however, results have been inconclusive and no previous study has considered the risk of IgAN in biopsy-verified CD. STUDY: We performed a population-based prospective cohort study. We identified 27,160 individuals with CD (Marsh stage III) and no previous renal disease through small-intestinal biopsy reports obtained between July 1969 and February 2008 in all (n=28) Swedish pathology departments. Individuals with IgAN were identified by biopsy reports acquired at the 4 Swedish pathology departments specialized in renal pathology. Cox regression analysis was used to determine the risk of future IgAN among individuals with CD compared with 133,949 age-matched and sex-matched reference individuals. RESULTS: Seven (0.026%) individuals with CD and 11 (0.008%) reference individuals developed IgAN. We found an increased risk of biopsy-verified IgAN among individuals with CD [hazard ratio, 3.03; 95% confidence interval, 1.22-7.56]. The risk increase remained statistically significant after adjustment for prior liver disease and country of birth. CONCLUSIONS: Individuals with CD suffer a 3-fold increased risk of future IgAN. Our findings warrant awareness of renal function in individuals with CD.
GOAL: To determine the risk of future biopsy-verified IgA nephropathy (IgAN) among individuals with biopsy-verified celiac disease (CD). BACKGROUND: Individuals with CD suffer increased risk of end-stage renal disease. An association between CD and IgAN has been suggested; however, results have been inconclusive and no previous study has considered the risk of IgAN in biopsy-verified CD. STUDY: We performed a population-based prospective cohort study. We identified 27,160 individuals with CD (Marsh stage III) and no previous renal disease through small-intestinal biopsy reports obtained between July 1969 and February 2008 in all (n=28) Swedish pathology departments. Individuals with IgAN were identified by biopsy reports acquired at the 4 Swedish pathology departments specialized in renal pathology. Cox regression analysis was used to determine the risk of future IgAN among individuals with CD compared with 133,949 age-matched and sex-matched reference individuals. RESULTS: Seven (0.026%) individuals with CD and 11 (0.008%) reference individuals developed IgAN. We found an increased risk of biopsy-verified IgAN among individuals with CD [hazard ratio, 3.03; 95% confidence interval, 1.22-7.56]. The risk increase remained statistically significant after adjustment for prior liver disease and country of birth. CONCLUSIONS: Individuals with CD suffer a 3-fold increased risk of future IgAN. Our findings warrant awareness of renal function in individuals with CD.
Authors: Katherine V Williams; Christina L Cristaldi; Rachel G Miller; Vincent C Arena; Ingrid Libman; Yihe Huang; Dorothy J Becker; Trevor J Orchard Journal: J Clin Endocrinol Metab Date: 2018-10-01 Impact factor: 5.958
Authors: Christina Papista; Sebastian Lechner; Sanae Ben Mkaddem; Marie-Bénédicte LeStang; Lilia Abbad; Julie Bex-Coudrat; Evangéline Pillebout; Jonathan M Chemouny; Mathieu Jablonski; Martin Flamant; Eric Daugas; François Vrtovsnik; Minas Yiangou; Laureline Berthelot; Renato C Monteiro Journal: Kidney Int Date: 2015-03-25 Impact factor: 10.612
Authors: Sang Hoon Woo; Tara K Sigdel; Van T Dinh; Minh-Thien Vu; Minnie M Sarwal; Richard A Lafayette Journal: Clin J Am Soc Nephrol Date: 2014-12-26 Impact factor: 8.237
Authors: Simon Jarrick; Sigrid Lundberg; Johan Sundström; Adina Symreng; Anna Warnqvist; Jonas F Ludvigsson Journal: BMC Nephrol Date: 2021-05-05 Impact factor: 2.388